Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Midatech Pharma stock price, quote, forecast and news

MTPH.L
GB00BKT14T00

Price

0.04
Today +/-
+0
Today %
+0 %
P

Midatech Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Midatech Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Midatech Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Midatech Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Midatech Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Midatech Pharma Stock Price History

DateMidatech Pharma Price
4/25/20230.04 undefined
4/24/20230.04 undefined

Midatech Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Midatech Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Midatech Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Midatech Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Midatech Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Midatech Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Midatech Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Midatech Pharma’s growth potential.

Midatech Pharma Revenue, EBIT and net profit per share

DateMidatech Pharma RevenueMidatech Pharma EBITMidatech Pharma Net Income
2021578,000 undefined-7 M undefined-5.46 M undefined
2020343,000 undefined-10.67 M undefined-22.19 M undefined
2019674,000 undefined-11.32 M undefined-10.09 M undefined
20181.94 M undefined-11.82 M undefined-15.03 M undefined
2017989,000 undefined-11.78 M undefined-16.06 M undefined
20161.32 M undefined-9.65 M undefined-20.16 M undefined
20151.38 M undefined-9.93 M undefined-10.1 M undefined
2014157,000 undefined-9.69 M undefined-8.82 M undefined
2013150,000 undefined-4.5 M undefined-4.08 M undefined
2012280,000 undefined-6.24 M undefined-6.12 M undefined
2011310,000 undefined-5.74 M undefined-5.74 M undefined

Midatech Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (k)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021
00001,0001,00001,000000
-----------
----100.00------
00001,000000000
-5-6-4-9-9-9-11-11-11-10-6
-----900.00-900.00--1,100.00---
-5-6-4-8-10-20-16-15-10-22-5
-20.00-33.33100.0025.00100.00-20.00-6.25-33.33120.00-77.27
28.4228.4228.420.461.441.832.63.10.922.144.03
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Midatech Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Midatech Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20112012201320142015201620172018201920202021
                     
4.180.152.3930.3316.1817.6113.22.3410.937.5510.06
0.481.180.160.460.991.432.231.320.990.10.03
0.620.761.860.842.412.312.041.951.821.381.06
00004598179410000
00-310-31129813816200258607
5.282.094.131.3220.3322.318.585.6213.749.2711.76
1.021.120.681.521.982.772.531.982.150.541.15
10501000000000
0.020.20.380.430.390.450.470.472.6300
00010.828.8816.6814.210.0810.0900
0002.2912.4614.4913.442.292.2900
00000000000
1.051.371.0715.0443.7134.3930.6414.8317.160.541.15
6.333.465.1746.3564.0456.6949.2220.4430.99.8212.91
                     
0.010.010111111.021.061.1
19.9819.9821.0231.6431.6447.2152.9452.9465.8874.3683.43
-21.04-26.88-20.48.5513.65-6.11-21.65-36.72-46.84-68.71-74.08
0.110.140.140.790.593.622.39-0.3-0.5100
00000000000
-0.94-6.750.7641.9946.8945.7234.6816.9219.566.7210.45
1.371.940.520.522.293.272.270.290.730.340.49
000.060.063.123.091.031.770.770.55
0.460.460.470.473.273.542.640.792.771.680.66
00000000000
1.133.351.250.490.440.540.360.370.410.20.15
2.965.752.31.549.19.358.362.475.672.991.84
4.294.452.121.491.511.626.190.885.670.060.62
0.01000.356.55000000
00000001650500
4.34.452.121.848.061.626.191.055.670.110.62
7.2610.24.423.3817.1510.9714.553.5211.343.12.46
6.323.455.1845.3764.0456.6949.2220.4430.99.8212.91
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Midatech Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Midatech Pharma's financial health and stability.

Assets

Midatech Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Midatech Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Midatech Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Midatech Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20112012201320142015201620172018201920202021
-6-6-4-8-10-20-16-15-10-22-5
00000421110
00000000000
01020100300
0001-2100-111-1
00000000000
00000-1-1-1-1-1-1
-5-4-4-5-12-13-12-13-6-9-6
000-10-1-10000
0000-1-1-19-320
00000009-320
00000000000
0100004-53-60
70533015501499
8163401510-61838
000000001,00000
00000000000
3-4227-141-4-108-32
-5.3-5.24-4.49-6.49-13.35-14.45-14.44-13.69-6.81-9.51-6.33
00000000000

Midatech Pharma stock margins

The Midatech Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Midatech Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Midatech Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Midatech Pharma's sales revenue. A higher gross margin percentage indicates that the Midatech Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Midatech Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Midatech Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Midatech Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Midatech Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Midatech Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Midatech Pharma Margin History

Midatech Pharma Gross marginMidatech Pharma Profit marginMidatech Pharma EBIT marginMidatech Pharma Profit margin
202194.91 %-1,210.73 %-944.64 %
202094.91 %-3,111.08 %-6,469.1 %
201994.91 %-1,679.23 %-1,496.29 %
201894.91 %-609.65 %-775.54 %
201794.91 %-1,190.7 %-1,624.27 %
201694.91 %-729.55 %-1,523.96 %
201594.91 %-721.96 %-734.47 %
201494.91 %-6,170.06 %-5,619.11 %
201394.91 %-3,000 %-2,720 %
201294.91 %-2,228.57 %-2,185.71 %
201194.91 %-1,851.61 %-1,851.61 %

Midatech Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Midatech Pharma earnings per share therefore indicates how much revenue Midatech Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Midatech Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Midatech Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Midatech Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Midatech Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Midatech Pharma Revenue, EBIT and net profit per share

DateMidatech Pharma Sales per ShareMidatech Pharma EBIT per shareMidatech Pharma Earnings per Share
20210.14 undefined-1.74 undefined-1.36 undefined
20200.16 undefined-4.98 undefined-10.36 undefined
20190.74 undefined-12.35 undefined-11 undefined
20180.62 undefined-3.81 undefined-4.85 undefined
20170.38 undefined-4.52 undefined-6.17 undefined
20160.72 undefined-5.27 undefined-11.01 undefined
20150.95 undefined-6.88 undefined-7 undefined
20140.34 undefined-20.99 undefined-19.11 undefined
20130.01 undefined-0.16 undefined-0.14 undefined
20120.01 undefined-0.22 undefined-0.22 undefined
20110.01 undefined-0.2 undefined-0.2 undefined

Midatech Pharma business model

Midatech Pharma is an international biotechnology company specializing in the development and commercialization of innovative therapeutic products based on nanotechnology. The company was founded in 2000 and is headquartered in the UK. Its business model focuses on identifying disease areas with high medical needs and limited availability of effective therapies. By using nanoparticles, drugs are targeted to specific cells or tissue areas, increasing efficacy while minimizing side effects. Midatech Pharma has specialized in researching and developing products for rare diseases and cancer, with three business divisions: Midatech Pharma US, Midatech Pharma Europe, and Midatech Pharma Asia. Midatech Pharma US, located in Philadelphia, focuses on developing drugs for rare diseases, particularly for neurological disorders such as brain tumors and epilepsy. It has already received approvals for two novel drugs, including a spray for acute epilepsy seizures and a nasal spray formulation for treating carcinoid tumors. Midatech Pharma Europe, based in Bilbao, Spain, specializes in manufacturing and developing drugs for cancer, including innovative nanotechnology-based therapies for prostate cancer, pancreatic cancer, and hepatocellular carcinoma. The company has conducted several clinical studies in Europe and the US, including successful phase II trials for a drug treating pancreatic cancer. Midatech Pharma Asia, located in China, focuses on developing and marketing drugs for the Asian market, collaborating closely with local partners to establish a comprehensive distribution network. The company has already introduced several drugs for cancer and other diseases to the Asian market. Key products of Midatech Pharma include MTX110, an innovative drug for treating DIPG (diffuse intrinsic pontine glioma); MTX102, a nasal spray for treating benign carcinoid tumors; and MTX225, a novel drug formulation for treating prostate cancer. Overall, Midatech Pharma has established itself as a leading company in the field of nanotechnology-based drug development in recent years. With its focus on rare diseases and the synergy of innovation and market proximity, the company is well positioned for future success. Midatech Pharma is one of the most popular companies on Eulerpool.com.

Midatech Pharma SWOT Analysis

Strengths

Midatech Pharma PLC has a strong pipeline of innovative pharmaceutical products, which provides a solid foundation for future growth and potential revenue streams.

The company has a diverse portfolio, targeting various therapeutic areas, allowing for flexibility and adaptability to changing market needs.

Midatech Pharma PLC has a strong intellectual property portfolio, safeguarding its innovation and providing a competitive advantage in the market.

Weaknesses

The company heavily relies on external funding to support its research and development activities, which may lead to funding uncertainties and potential delays in product development.

Midatech Pharma PLC currently operates in a highly competitive pharmaceutical industry, which may pose challenges in terms of market share and pricing strategies.

The company's geographic presence is limited, and it may face difficulties in expanding globally and accessing new markets.

Opportunities

The increasing demand for targeted therapies and personalized medicine presents a significant opportunity for Midatech Pharma PLC, given its expertise in this area.

Collaborations and partnerships with larger pharmaceutical companies can provide access to additional resources, expertise, and distribution channels.

The company can leverage advancements in technology, such as nanotechnology, to enhance its drug delivery systems and develop innovative solutions.

Threats

Regulatory challenges and stringent approval processes in the pharmaceutical industry may hinder the timely commercialization of the company's products.

The potential emergence of new competitors with similar or superior products can pose a threat to Midatech Pharma PLC's market position.

Changes in healthcare policies or reimbursement systems may impact the pricing and affordability of the company's products.

Midatech Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Midatech Pharma historical P/E ratio, EBIT, and P/S ratio.

Midatech Pharma shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Midatech Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Midatech Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Midatech Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Midatech Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Midatech Pharma Stock splits

In Midatech Pharma's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Midatech Pharma.

Midatech Pharma list of shareholders

%
Name
Stocks
Change
Date
59.94398 % A&B (HK) Company, Ltd.5,194,805011/15/2022
59.94398 % CMS Medical Venture Investment (HK), Ltd.5,194,805011/15/2022
5.98113 % Wings Establishment518,331011/15/2022
4.03873 % Intuitive Investments Group PLC350,000350,0006/29/2021
36.24727 % Armistice Capital LLC3,141,225-6,708,1001/12/2023
30.91424 % Lombard Odier Asset Management (Europe) Ltd2,679,059-4,857,50012/15/2022
125.01587 % L1 Capital Global Opportunities Master Fund Ltd.10,834,00010,834,0002/15/2023
125.01587 % Anson Funds Management LP.10,834,00010,834,0002/15/2023
125.01587 % S.H.N. Financial Investments10,834,00010,834,0002/15/2023
0.95159 % Ippon Capital SA82,466011/15/2022
1
2
3

Most common questions regarding Midatech Pharma

What values and corporate philosophy does Midatech Pharma represent?

Midatech Pharma PLC is a globally renowned biotechnology company focused on developing innovative therapeutic solutions. With a strong commitment to advancing patient care, Midatech Pharma PLC prioritizes values of excellence, integrity, and scientific rigor in its operations. The company's corporate philosophy revolves around leveraging unique drug delivery technologies to improve the effectiveness and targeting of therapies. Midatech Pharma PLC's dedication to precision medicine and personalized treatment approaches sets it apart in the healthcare industry. By aligning innovation with patient needs, Midatech Pharma PLC strives to make a significant impact on the lives of individuals globally.

In which countries and regions is Midatech Pharma primarily present?

Midatech Pharma PLC is primarily present in the United Kingdom, United States, and Spain. Their presence is also notable in other European countries such as Germany and France. As a global pharmaceutical company, Midatech Pharma PLC is committed to advancing and delivering innovative therapies worldwide.

What significant milestones has the company Midatech Pharma achieved?

Midatech Pharma PLC has achieved several significant milestones in its history. Firstly, the company successfully completed the acquisition of Zuplenz®, a commercially available cancer supportive care product. Additionally, Midatech received approval for Monosulfiram, an innovative topical treatment for scabies. The company also advanced its internal pipeline, with positive pre-clinical results for its sustained-release biodegradable polymer technology. Furthermore, Midatech obtained regulatory clearance to initiate clinical trials for MTX110, a treatment for childhood brain cancer. These achievements demonstrate Midatech Pharma PLC's dedication to developing and commercializing innovative therapies for unmet medical needs, solidifying its position as a leader in the pharmaceutical industry.

What is the history and background of the company Midatech Pharma?

Midatech Pharma PLC is a British pharmaceutical company founded in 2000. With a strong focus on developing and commercializing innovative medicines, Midatech is dedicated to addressing unmet medical needs. Their proprietary drug delivery technologies enable targeted therapies, enhancing the potential for efficacy and reducing side effects. Over the years, Midatech has built a diverse pipeline of products across various therapeutic areas, including oncology and immunology. Committed to advancing healthcare, Midatech continues to collaborate with partners and conduct extensive research to develop novel therapies for the benefit of patients worldwide.

Who are the main competitors of Midatech Pharma in the market?

The main competitors of Midatech Pharma PLC in the market include established pharmaceutical companies such as AstraZeneca, Pfizer, and GlaxoSmithKline. These companies also operate in the field of developing and commercializing innovative pharmaceutical products and therapies. Despite facing intense competition, Midatech Pharma PLC has strategically positioned itself through its unique drug delivery technologies and focus on niche therapeutic areas. By continuously advancing its pipeline of drugs, Midatech Pharma PLC aims to differentiate itself in an increasingly competitive market.

In which industries is Midatech Pharma primarily active?

Midatech Pharma PLC is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Midatech Pharma?

The business model of Midatech Pharma PLC revolves around developing and commercializing innovative pharmaceutical products. Midatech Pharma specializes in the research and development of targeted therapies to improve the delivery and efficacy of medications. Their focus lies in creating gold nanoparticle-enabled therapies (GNP) for the treatment of various diseases, including cancer and diabetes. By utilizing their expertise in nanotechnology, Midatech Pharma aims to enhance drug delivery to specific disease sites within the body, minimizing side effects and improving patient outcomes. With a strong commitment to research and development, Midatech Pharma strives to bring novel treatment options to patients worldwide.

What is the P/E ratio of Midatech Pharma 2024?

The P/E ratio cannot be calculated for Midatech Pharma at the moment.

What is the P/S ratio of Midatech Pharma 2024?

The P/S cannot be calculated for Midatech Pharma currently.

What is the AlleAktien quality score of Midatech Pharma?

The AlleAktien quality score for Midatech Pharma is 4/10.

What is the revenue of Midatech Pharma 2024?

The revenue cannot currently be calculated for Midatech Pharma.

How high is the profit of Midatech Pharma 2024?

The profit cannot currently be calculated for Midatech Pharma.

What is the business model of Midatech Pharma

Midatech Pharma PLC is a global biopharmaceutical company focused on innovative technologies for the development and marketing of drugs. The company specializes in nanotechnology and uses this technology to develop groundbreaking solutions for drug development. It has two main business areas: core platforms and product development. The core platforms include the nanoparticle platform and the magnetic-responsive platform, which allow for the precise size and shape of drug molecules to be targeted and efficiently delivered in the body. The company is currently involved in the research and development of cancer and diabetes drugs, with multiple candidates in various clinical phases. It has also formed partnerships with other companies and signed agreements to expand the use of its nanoparticle technology in defense and security applications. Moreover, it has expanded its infrastructure through the acquisition of DARA BioSciences, strengthening its presence in the US and improving access to key markets. Overall, Midatech Pharma PLC has achieved a leading position in nanotechnology and is committed to developing drugs for serious diseases like cancer and diabetes. It has also strengthened its infrastructure and presence in key markets through partnerships and acquisitions.

What is the Midatech Pharma dividend?

Midatech Pharma pays a dividend of 0 GBP distributed over payouts per year.

How often does Midatech Pharma pay dividends?

The dividend cannot currently be calculated for Midatech Pharma or the company does not pay out a dividend.

What is the Midatech Pharma ISIN?

The ISIN of Midatech Pharma is GB00BKT14T00.

What is the Midatech Pharma ticker?

The ticker of Midatech Pharma is MTPH.L.

How much dividend does Midatech Pharma pay?

Over the past 12 months, Midatech Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Midatech Pharma is expected to pay a dividend of 0 GBP.

What is the dividend yield of Midatech Pharma?

The current dividend yield of Midatech Pharma is .

When does Midatech Pharma pay dividends?

Midatech Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Midatech Pharma?

Midatech Pharma paid dividends every year for the past 0 years.

What is the dividend of Midatech Pharma?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Midatech Pharma located?

Midatech Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Midatech Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Midatech Pharma from 9/11/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.

When did Midatech Pharma pay the last dividend?

The last dividend was paid out on 9/11/2024.

What was the dividend of Midatech Pharma in the year 2023?

In the year 2023, Midatech Pharma distributed 0 GBP as dividends.

In which currency does Midatech Pharma pay out the dividend?

The dividends of Midatech Pharma are distributed in GBP.

All fundamentals about Midatech Pharma

Our stock analysis for Midatech Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Midatech Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.